The human placental anti-aggregating factor is neither prostacyclin, nor a prostacyclin metabolite

Using PGH₂ as substrate, we have previously demonstrated that human placenta synthetizes mainly PGE₂, TxB₂ and PGD₂(1,2). Other reports have shown that placental tissue generates a substance which inhibits ADP-induced platelet aggregation and which was supposed to be PGI₂ (3). The present study indicates that the stability of that substance is different from the stability of prostacyclin (released by umbilical artery pieces). By GC-MS and multiple ion-monitoring, we have shown the presence of 6 keto-PGF_1α (the stable metabolite of PGI₂) in the umbilical artery incubation medium, while no trace of 6-keto-PGF_1α could be found in the placental medium. No conversion of AA to 6-keto-PGF_1α by placental microsomes was observed, even in the presence of antioxidants. The placenta possesses, in addition to the known 15-OH-PGDH and Δ-13 reductase activities, a weak 9 OH pGDH which is specific for PGF_2α (and not PGI₂ nor 6-keto-PGF_1α). GC-MS analysis is showed that the expected metabolites of PGI₂ through those three enzymes were not found in the placental medium, indicating that neither PGI₂ synthesis nor metabolism could be demonstrated in the placenta.